Personalized ctDNA Monitoring Can Predict Outcomes in Advanced Melanoma
Source: Cancer Therapy Advisor, March 2023
Personalized circulating tumor DNA (ctDNA) monitoring can predict outcomes during and after treatment in patients with advanced melanoma, according to research published in Cancer.
Researchers found that ctDNA status could predict distant metastasis-free survival (DMFS) and progression-free survival (PFS) during and after treatment with immune checkpoint inhibitors (ICIs).
The researchers used a personalized, tumor?informed ctDNA assay on 555 prospectively collected plasma samples from 69 patients with advanced melanoma. The patients were divided into 3 cohorts.